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Abstract: This review discusses the methodology of the standardized on-the-road driving test 
and standard operation procedures to conduct the test and analyze the data. The   on-the-road 
driving test has proven to be a sensitive and reliable method to examine driving ability after 
administration of central nervous system (CNS) drugs. The test is performed on a public highway 
in normal traffic. Subjects are instructed to drive with a steady lateral position and constant 
speed. Its primary parameter, the standard deviation of lateral position (SDLP), ie, an index of 
‘weaving’, is a stable measure of driving performance with high test–retest reliability. SDLP 
differences from placebo are dose-dependent, and do not depend on the subject’s baseline 
driving skills (placebo SDLP). It is important that standard operation procedures are applied 
to conduct the test and analyze the data in order to allow comparisons between studies from 
different sites.
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Introduction
Driving a car is a daily activity for many people, including individuals who are treated 
with central nervous system (CNS) medication. Impaired driving is an important public 
health issue, as the driver puts himself and others at risk of injury. Therefore, it is 
important that the effects of medicines on driving ability are examined in a valid and 
reliable manner that predicts what happens when individuals actually drive. Currently, 
the on-the-road driving test is regarded as the “gold standard” to determine whether 
drugs affect driving ability.1 The on-the-road driving test was developed by O’Hanlon 
and his colleagues2–4 and has been applied in psychopharmacological research for 
30 years. Although the methodology is highly standardized, guidelines clearly defining 
the conduct of the test and how the data is interpreted have not been published. This 
article gives an overview of the methodology of the on-the-road driving test, and the 
measurement and interpretation of its primary parameter, the standard deviation of 
lateral position (SDLP). This article summarizes standard operation procedures (SOPs) 
for conducting the highway driving test, editing and analyzing the data, and calcula-
tion and interpretation of SDLP. Recently, various research groups have implemented 
SDLP as an outcome measure in their driving (simulator) tests. Adopting consistent 
methodologies is critical to enable comparison of driving data from different research 
labs using different assays.International Journal of General Medicine 2011:4
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Figure 1 The standard deviation of lateral position (SDLP).
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The on-the-road driving test
The on-the-road driving test is performed on a public 
  highway in normal traffic. Although the on-the-road test is 
conducted in the presence of a licensed driving instructor who 
has access to dual controls, the test conditions reflect actual 
driving and associated risks. The on-the-road driving test is 
performed on a 100 km highway segment. Participants are 
instructed to drive with a steady lane position and constant 
speed. The primary outcome measure of vehicle control is 
the standard deviation of lateral position (SDLP), ie, the 
amount of “weaving” of the car (see Figure 1). The secondary 
outcome measure is the standard deviation of speed (SDS). 
Figure 1 illustrates that SDLP is a measure of vehicle control. 
If vehicle control becomes less, SDLP values increase.
Since SDLP increment may ultimately result in lane 
crossings into the road shoulder and adjacent traffic lane, 
SDLP can also be regarded as a potential index of driving 
safety. Thus, the construct validity of the driving test, ie, 
measurement of vehicle control, can be regarded as high. 
Further, the driving test has a much higher content validity 
(ie, ecological validity) when compared to closed road tests, 
driving simulators, and psychometric tests. That is, although 
subjects have to follow certain instructions while driving (eg, 
maintain a steady lane position and constant speed), and a 
driving instructor accompanies the participant, the test is 
the closest representation of normal driving and associated 
risks.
Up to now, this methodology has been applied in over 50 
trials in The Netherlands. Dose-dependent SDLP changes 
have been reported for various CNS compounds, including 
alcohol and drugs of abuse,5 hypnotics,6,7 anxiolytics,8 
antidepressants,9 and antihistamines.10
Setting and duration of the test
The on-the-road driving test is conducted over a two-lane 
public highway with normal traffic density and takes about 
1 hour to complete. At Utrecht University, the test consists 
of two 50 km parts and a turning point (eg, Utrecht → 
Arnhem → Utrecht). The test can be performed at any time 
of day or night, but generally rush hours are avoided to reduce 
the likelihood of significant data loss due to maneuvers 
required in heavy traffic (these maneuvers are edited out 
when preparing the data for analyses).
The relatively long distance of the test was chosen on 
purpose to ensure the monotonous character of the test and 
to incorporate the known finding of a decline in vigilance 
with time on task. Thus, potential vigilance decrements can 
be measured. In tests of short duration, by increased effort 
participants can overcome possible drug-induced impair-
ments and vigilance effects are absent.
Because other traffic is present, participants have to react 
to other cars, and may experience unexpected events such as 
traffic jams, emergency stops, etc. This heightens the eco-
logical validity (ie, the feeling of ‘real driving’) of on-road 
driving relative to driving simulators. For safety, a licensed 
driving instructor with dual controls accompanies the partici-
pant. The presence of the investigator in the back of the car is 
important as he has knowledge about the (medical)   condition International Journal of General Medicine 2011:4
Figure 2 One of the instrumented cars of Utrecht University.
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of the patient, and is familiar with the potential adverse 
effects of the drugs that are under investigation. Moreover, 
the investigator monitors the recording of the data and makes 
notes about events that happen during the driving test (eg, 
start and end of overtaking maneuvers). Thus, to ensure data 
quality, it is preferable that the investigator who accompanied 
the driving test should edit the data obtained.
Instructions for participants
Although for many people driving is a daily activity, it is 
necessary to train participants in the procedures of the driving 
test. Participants should be familiarized with the instrumented 
vehicle and its equipment, because this may differ from their 
own car. For example, the test vehicles used in The Netherlands 
are station wagons, while many people drive regular cars. To 
this extent, a full 100 km training test drive is made on the 
same highway track where the research will take place.
The two main instructions for participants are:
1.  Maintain a steady position within the traffic lane during 
the entire test
2.  Maintain a constant speed (usually 95 km/hour).
Participants are free to choose their preferred position 
within the traffic lane. Thus, participants should not be 
directed to drive exactly in the middle of the road, because 
this may create an unnatural situation if they normally do 
not drive in that position.
Mean lateral position (MLP) and mean speed (MS) are 
determined, and the variation in these two outcome measures 
shows how well subjects were able to conduct the test according 
to these instructions. A secondary parameter is the standard 
deviation of speed. This parameter also measures vehicle con-
trol, but drug-induced impairment is less clearly observed, and 
speed variability usually has fewer consequences for traffic 
safety than weaving of the car (SDLP).
Data recording – the 
instrumented car
A camera is mounted on the roof of the car to measure 
the vehicle’s lateral position relative to the painted stripe 
road delineation (see Figures 2 and 3). Two infrared lights 
1 m
Left lane Right lane
Road
shoulder
2.5 m0 .5 m
0 V− 5 V +5 V
1 m
Figure 3 Schematic representation of the on-the-road driving test.International Journal of General Medicine 2011:4
0
L
a
t
e
r
a
l
 
p
o
s
i
t
i
o
n
 
(
m
)
1
1
90
S
p
e
e
d
 
(
k
m
/
h
r
)
P
l
a
c
e
b
o
60
120
Left
Right
0
L
a
t
e
r
a
l
 
p
o
s
i
t
i
o
n
 
(
m
)
1
1
90
S
p
e
e
d
 
(
k
m
/
h
r
)
L
o
p
r
a
z
o
l
a
m
 
(
2
 
m
g
)
60
Distance travelled (km)
01 02 03 04 0
Stop
50
120
Left
Right
Figure 4 examples of lateral position and speed changes over distance traveled. 
Adapted with permisison from Volkerts eR, de Vries G, Meijer T, et al. Driving 
performance  the  day  after  use  of  loprazolam,  flunitrazepam  and  placebo.  VSC, 
Report VK 83-04, Traffic Research Centre, Groningen, The Netherlands, 1984.11
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enable data collection after sundown or during bad weather 
conditions. In addition, a filter can be used to prevent 
reflection of sunlight in case of wet road conditions. Speed 
is measured from a pulse generator triggered by magnetic 
induction at a rate proportional to the revolutions of the 
wheels. Speed and lateral position data is continuously 
recorded at a rate of 2 Hz.
Figure 3 shows that the camera measures the distance 
from the car relative to the painted striped delineation in 
the middle of the road. The camera covers about 3 meters. 
When the car moves towards or into the left traffic lane (for 
example to overtake another car), at some point the camera 
can no longer capture the painted striped delineation in the 
middle of the road. From that moment, the camera switches 
to the left delineation of the left traffic lane. In the raw data 
from the test, this typically results in an easy-to-recognize 
peak in the data, that is also seen when the car returns to the 
right traffic lane. In the event that the car crosses the left 
delineation of the left traffic lane by more than 50 cm (a rare 
event) the signal is lost and no data is collected.
Raw data
During the driving test, lateral position and speed data is col-
lected at a speed of 2 Hz. Figure 4 shows a typical example 
of this raw data.11 Data from two driving tests of a participant 
in a hypnotic study are shown. The top figure shows raw data 
from a driving test 10 hours after bedtime administration of 
placebo; the bottom figure shows raw data collected 10 hours 
after bedtime administration of loprazolam (2 mg). One meter 
left indicates left wheel excursion into the adjacent traffic 
lane and one meter right indicates right wheel excursion into 
the road shoulder. Note, the driving test in the loprazolam 
condition was stopped after 40 km, because the participant 
was too sedated to continue driving.11
Data editing: Standard Operation 
Procedures
The raw data from the driving test must be edited before 
SDLP is computed because it contains artifacts. This is 
always done before the blind is broken. Because the driving 
test is performed in normal traffic, events may occur where a 
participant can not obey the two instructions of maintaining a 
steady lane position and constant speed. For example, passing 
maneuvers, traffic jams, and the turn-around point should 
be edited out from the data. Standard operation procedures 
(SOPs) describe rules on how to edit the data. These are sum-
marized in Figure 5. To ensure standardization in editing the 
data, it is important that editors are trained to use the SOPs.
Normal SDLP values
The SDLP is calculated the following way:
•	 Calculate the mean lateral position (MLP) for the entire 
drive (eg, the 100 km test)
•	 Calculate the standard deviation of the MLP ( = SDLP) 
across all of the samples taken in the 100 km drive.
The equation to calculate a standard deviation is:
When X is the lateral position (determined for each valid 
data point) with a mean value µ:
  MLP [X] = µ  (1)
In equation (1), MLP (mean lateral position) denotes the 
average of X. The standard deviation of X is the quantity:
  SDLP MLPX =− µ)
2 [( ]   (2)
In other words, SDLP is the square root of the variance of 
X, ie, it is the square root of the average value of (X − µ)2.International Journal of General Medicine 2011:4
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Figure 5 Standard operation procedures to edit the raw data of the driving test. The top figure shows the mean lateral position (MLP) of the car. The bottom figure shows 
the mean speed (MS) of the car. Standard operation procedures: A) Start of the test: data is deleted until the subject drives 95 km/h in gear number 5. B) An overtaking 
maneuver: data is deleted from the start of accelerating to overtake, or moving to the left lane, until the car is returned completely back on the right lane and its speed 
is returned to 95 km/hour. C) Attempt to overtake: data is deleted from the first attempt to overtake. D) Between two overtaking maneuvers: data is deleted when the 
distance between the two maneuvers is at less than 600 meters. E) Out of the detection range: data is deleted. F) Collisions, off road crashes, other events requiring stopping 
or slowing speed: data is deleted from the moment of the crash until the car drives 95 km/hour in gear number 5. Cut-off points for editing are indicated by |.
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Figure 6 depicts individual SDLP values from n = 268 
healthy volunteers who performed a driving test after 
administration of placebo.2,12–24 Whereas the mean SDLP is 
18.79 cm, values range from 9 cm up to 30 cm and higher. 
Thus, SDLP values differ greatly between individual 
drivers.
Most studies that tested subjects on different occasions 
support the idea that SDLP is a very reliable measure. That 
is, although SDLP varies greatly between subjects, it is a 
stable measure within subjects across time. This is illus-
trated by Figure 7, which shows the relationship between 
morning and afternoon driving test results in n = 98 healthy 
volunteers.2,12–18 The participants received placebo at bedtime 
and performed a driving test 9–10 and 16–17 hours after 
intake. The mean SDLP of the morning and afternoon   driving 
tests did not differ from each other (19.44 and 19.69 cm, 
respectively). Importantly, it is evident from Figure 7 that 
the test–retest reliability is high (r = 0.80).
Weather conditions 
and traffic density
Driving tests are conducted throughout the year, under 
different weather conditions. Excessive sunshine and 
reduced   visibility due to rain and clouds can interfere with 
  measurements made by the camera. This reduces the per-
centage of clean data from the driving test that can be used 
for statistical analysis. There are no rules for a minimum of 
required clean data points from a given driving test. Under 
normal weather conditions and traffic density 60%–80% of 
the data is retained for the statistical analyses and there are 
no major changes with traffic or inclement weather.
Figure 8 shows that in winter the percentage of clean 
data is 5% to 10% lower compared to the remainder of the 
year.21–23,25 It is important to note that SDLP values do not 
differ significantly during the year.
It has been suggested that differences in traffic density 
may affect driving performance. Since the aim of a highway 
test is to measure driving performance in monotonous con-
ditions, increased traffic density may increase participants’ 
alertness because they have to respond continuously to other 
traffic. Increased alertness may in turn improve   driving 
performance. Also of concern is the fact that increased 
numbers of overtaking maneuvers and risk of traffic jams 
will significantly reduce the clean data that can be used for 
statistical analyses. To reduce this unwanted effect, driving 
tests should not be conducted during rush hours. Outside rush 
hours, the traffic density is fairly constant.
Safety issues and premature 
stopping of the test
Over the past 30 years of applying the on-the-road driving 
test, no accidents have occurred. Nevertheless, several drugs 
visibly impaired driving performance of participants. Thus, 
the participants are accompanied by a driving instructor who 
has dual controls to take over before it actually becomes 
unsafe to continue driving. According to Dutch law, drivers 
should stop driving if they perceive their driving is dangerous. 
As long as neither the driver nor other traffic are at risk, the International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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test is continued. Both the participant and the driving instruc-
tor can decide to stop the driving test. The latter is important, 
since participants do not always recognize that their driving is 
impaired. In that case, only the distance that is actually driven 
is used for the statistical analyses. Driving tests are stopped 
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Figure 7 Test–retest reliability of SDLP measurement.
Data from n = 98 healthy volunteers (data from references 2, 12–18). 
Note: Driving tests were performed in the morning or afternoon following bedtime 
administration of placebo (9–10 hours and 16–17 hours after intake).
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Figure 8 SDLP values and weather conditions.
Data from 174 driving tests of healthy volunteers who received placebo treatment (Data from references 21–23, 25).
for example when participants are very sleepy. SDLP values 
at that time are often, but not always, high (eg, above 40 cm), 
and participants may actually drive into the road shoulder 
and adjacent traffic lane. An example of such a driving test is 
shown in Figure 4. After 40 km the driving test was stopped. 
It is likely that driving performance would have further dete-
riorated if the test had been continued. Therefore, the SDLP 
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Figure 6 SDLP values obtained after administration of placebo.
Data from references 2, 12–24.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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value over the distance that was   actually driven should be 
regarded as the lower cutoff point and an underestimation 
of the real impairment. For stopped driving tests, SDLP is 
calculated over the distance that was actually driven. One 
should not apply a last-observation-carried forward proce-
dure, in which the SDLP value of the last completed 10 km 
segment is used for the missing segments.
The number of stopped driving tests, if frequent in any 
condition, may be an indicator of the frequency of impaired 
driving but is a poor indicator of the magnitude of impair-
ment caused by a drug.3 This is caused by the fact that the 
decision to stop a driving test or continue driving is a safety 
assessment made by the participant or the driving   instructor. 
Therefore, in some studies, driving tests have also been 
stopped when absolute SDLP values were fairly normal, eg, 
ranging between 20 and 24 cm.26 Hence, SDLP values of 
driving tests that were completed can be higher than tests that 
were stopped. This highlights the importance of including 
data from stopped driving tests in the statistical analysis.
SDLP values over distance  
traveled: 10 km segments
The standardized 100 km driving test takes about 1 hour to 
complete. Because the driving test is in part a vigilance test, 
it is common to see performance decrement over time. The 
usual method to illustrate the vigilance effect is examining 
the change in SDLP across the 10 km segments. It is possible 
to use shorter segments (eg, 5 km), however it can be ques-
tioned if this is useful. The shorter the examined segment, the 
smaller the corresponding SDLP values. This is illustrated in 
Table 1. While the mean SDLP over 100 km is 15.3 cm, the 
average of the 10 km segments is 13.5 cm, and even lower 
for 5 km segments (12.1 cm) and 2 km segments (10.6 cm). 
The reason for lower SDLP values in shorter segments is 
that the MLP has less opportunity to show large changes if 
the distance is shorter. In fact, if the length of the segment 
approaches zero, SDLP does too. Therefore the SDLP mea-
sured over short distance of a segment is an underestimation 
of the overall 100 km SDLP.
The following rules apply for calculating the SDLP of 
a given segment:
•	 Calculate the mean lateral position (MLP) for the segment 
of interest
•	 Calculate the standard deviation of the MLP of that 
  segment (= SDLP).
A typical example of a driving performance decrement 
across the 100 km driving test is shown in Figure 9, summa-
rizing data from 214 driving tests performed in the placebo 
condition by healthy volunteers.11,12,17,18,22,23.
From Figure 9 (left panel), it is evident that SDLP values 
increase during the test. A temporary reduction in SDLP is 
seen after the ‘turning point’ (segment 6). Half way (ie, at 
the turning point), participants leave the highway for about 
2–5 minutes to turn around and continue the second part 
of the test. As this represents an increase in activities and 
  stimulation for the driver a transient improvement of driving 
is typically seen (ie, a reduced SDLP value in   segment 6). 
A similar progressive performance decrement is seen when 
driving after administration of sedative drugs, but SDLP 
values are higher in each segment. The right panel of 
  Figure 9 shows that SDLP continues to deteriorate when the 
duration of the driving test is further extended.27
It is important to note the overall 100 km SDLP is not 
the average of the SDLP values of the ten 10 km segments. 
Because the MLP of individual segments differ from each 
other, they also differ from the overall 100 km MLP that is 
used to calculate the SDLP. This is illustrated in Figure 10.
Figure 10 schematically summarizes two test drives. The 
SDLP computed for each 10 km segment equals 16 cm. In 
the top figure, the participant maintains a steady lane position 
within the traffic lane. As a result, the overall SDLP does 
not differ much from the SDLP measured in the individual 
Table 1 Data from one driving test, when using different length of segments
100 km Segment 10 × 10 km 20 × 5 km 50 × 2 km
15.3 0–10 km 12.1 12.5 12 No data No data 10.7 13.9 5.3
11–20 km 13.2 10.5 12.8 8.1 11 8.3 13 13
21–30 km 11.6 12.6 8.9 11.4 11.3 8.7 10 9.4
31–40 km 17.7 10 12.5 7.8 11.8 12.8 8.5 12.7
41–50 km 15.4 16.4 13.4 13.8 9.8 15.8 9.5 11.1
51.60 km 10.3 9.9 9.4 9.4 8.4 9.1 8.1 8.4
61–70 km 15.5 19.3 10 10.1 23.1 11 8 10
71–80 km 13.9 13.7 13.9 12.1 15.1 10.5 11.6 12.8
81–90 km 11 11.2 10.8 8.1 9 14.5 8.1 9.3
91–100 km 14.5 11.5 10.7 6.8 12 6.1 11.5 8International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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y = 23.6x0.14
R2 = 0.87
Performance decrement over time
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Figure 9 SDLP values over distance traveled. The left Figure shows SDLP values calculated for 10 km segments of 214 subjects who drove after receiving placebo (Data from 
references 11, 12, 17, 18, 22, 23). The right panel shows SDLP values obtained after 1, 4, and 8 hours of continuous driving (Data from reference 27).
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Figure 10 The impact of mean lateral position changes on SDLP.
Abbreviations: MLP, mean lateral position; SDLP, standard deviation of lateral position.
segments. The bottom figure shows a participant that was not 
maintaining a steady lane position. This results in a difference 
between the SDLP values of the individual segments (16 cm) 
and the overall SDLP (24 cm). The reason for this difference 
is the fact that the MLP of the segments is different from the 
MLP of the entire test. Thus, one may incorrectly conclude 
that driving performance of the participant is impaired. 
This underlines the importance of training and instructing 
participants to maintain a constant lane position throughout 
the entire driving test.
Subjective assessments
The use of subjective assessments can provide further insight 
into behavioral changes associated with CNS drugs. Two 
assessments that are routinely made after the driving test 
are subjective driving quality and mental effort required to 
perform the test.28,29 Measurements are conducted with visual 
analog scales (see Figure 11).
Perceived driving quality is important as this may differ 
significantly from actual driving performance. That is, 
participants may not acknowledge or even be aware of the International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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fact that their driving is impaired. This finding has been 
shown for various psychoactive drugs including alcohol and 
diphenhydramine.21,22 Clearly when aware of their impair-
ment they can make adjustments or even chose not to drive. 
However the lack of this awareness exacerbates the potential 
consequences of the impairment.
Sometimes participants do acknowledge that their 
driving is impaired, or they experience reduced alertness. 
In such instances, increased effort to perform the test may 
(partly) counteract the impairment. For example, no differ-
ence from placebo may be found after administration of a 
drug, but it takes participants much more effort to perform 
a driving test.24
Subjective assessments on driving quality, mental effort 
and alertness also provide information on subgroups of par-
ticipants that do experience adverse effects of a drug, while 
statistical analyses on a group level do not reveal overall 
differences from placebo.
Clinical relevance of statistical 
results
If the analysis reveals a statistically significant difference in 
SDLP between a drug and placebo, this does not automati-
cally imply that the difference has a meaningful relevance 
in terms of traffic safety.
It is important to have a clinical relevant cut-off point of 
impairment that facilitates the interpretation of results from 
driving studies measuring SDLP. Historical data is often 
used to serve as such a comparator. For example, a study 
by Louwerens et al provided SDLP changes from placebo 
when driving with different blood alcohol concentrations 
(BAC).30 These differences, corresponding to common legal 
limits for driving were +2.4 cm (BAC 0.05%) and +4.3 cm 
(BAC 0.08%). Many driving studies refer to these changes 
from placebo to contrast with the magnitude of impairment 
observed with a given drug. Looking at differences from 
placebo is justified because SDLP changes (at group level) 
Figure 11 Subjective assessments completed after the driving test. Subjects indicate their perceived driving quality (left figure) and perceived effort (right figure) by placing 
an ‘X’ at the vertical line.
I drove normally
I drove exceptionally well
Perceived driving quality scale
I drove exceptionally poorly
Please indicate the quality of your driving in the test you just 
finished by marking the scale with an ‘x’ at the appropriate place.
Extreme effort
Very great effort
Great effort
Considerable effort
Rather much effort
Some effort
A little effort
Almost no effort
Absolutely no effort
Perceived effort scale
Would you please, by means of placing an ‘x’ at the appropriate point
on the scale below, indicate how much effort it cost you to perform the
task you’ve just finished (translated from dutch)International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Figure 12 SDLP differences from placebo (cm) after administration of flurazepam (30 mg). When absolute placebo SDLP values increase, the difference from placebo does 
not (r = 0.16, n.s.). 
Data from reference 3, 15.
Predictive validity of SDLP
It is sometimes argued that SDLP is representative only of a sub-
task of driving (eg, road tracking ability), or that it is obtaining 
measurements only at the skill based (operational level) level 
of driving behavior. While it is correct that the performance 
measured by SDLP is conducted at an operational/control level 
and that it comprises road tracking, this does not preclude the 
concept that SDLP predicts overall vehicle control.
For a valid measure, it is essential that it predicts actual 
traffic safety, such as the likelihood of becoming involved in 
a traffic accident. Owens and Ramaekers31 conducted com-
parative analyses of data obtained from on-the-road driving 
tests as well as epidemiological data on crash risks. SDLP 
increment after consumption of different dosages of alcohol30 
and epidemiological studies relating BAC and accident data32 
showed a very high correlation (r = 0.99) between SDLP 
increment (relative to placebo) and indirectly, the risk of hav-
ing a traffic accident.31 Owens and Ramaekers found similar 
strong relationships for benzodiazepines (r = 0.96) and THC 
(r = 0.97). Although direct data relating change in SDLP to 
accidents is currently lacking, these data support the value 
of SDLP in its relationship to traffic accident risk.
Relationship with blood plasma 
concentration
Relative to placebo, a dose-related increment in SDLP is 
generally seen after treatment administration. In addition, 
are very stable and independent of the magnitude of baseline 
(placebo) SDLP values. This is shown in Figure 12, which 
depicts data from 73 driving tests performed after adminis-
tration of flurazepam (30 mg) and placebo.3,15 Contrary to 
what is sometimes suggested, it is evident from Figure 12 
that SDLP differences from placebo do not significantly 
differ between ‘good’ and ‘bad’ drivers. In line with earlier 
findings by O’Hanlon, absolute SDLP values are not reliable 
predictors of impairment seen after drug administration.3
Although the historical data may be used to interpret the 
magnitude of the SDLP impairment, it is strongly recom-
mended that an active comparator is incorporated into the 
study design. The positive control (verum) should be a drug 
that has been previously shown to impair driving ability in 
terms of significant increment in SDLP. Including a verum 
is important for three reasons: a) to show the sensitivity of 
the participant to drug-induced impairment, b) to confirm 
sensitivity of the driving test in the specific experiment, and 
c) to calibrate, through the active control, to other studies 
in the literature. The choice of a verum is arbitrary, and can 
be alcohol or a CNS drug. However, it is important that a 
verum is chosen that 1) the research team is familiar with, 
2) of which the magnitude of impairment is important, and 
3) has been demonstrated before to impair SDLP in an on road 
driving task. For example, when studying hypnotics zopiclone 
is often used, and when studying anxiolytics   diazepam could 
be included as the positive control.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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significant correlations of SDLP changes from placebo 
with blood plasma concentrations of drugs have also been 
found for dose averages of some but not all drugs.3 Driving 
  studies do not typically include blood sampling to examine 
the relationship between SDLP increment and blood plasma 
  concentration caused by the drugs under investigation. 
  Therefore, it is currently not possible to provide general 
  cut-off points for safe driving, based on the taken dosage 
and time after intake of a drug. Although the latter would 
be an important goal,3 this may also put drivers at potential 
risk, because this information could only be provided at a 
drug level (ie, a mean drug effect), and not tailored for indi-
vidual patients. Because of differences in drug metabolism 
in patients and the development of tolerance after repeated 
dosing, it is unlikely that this information can be determined 
on the individual patient level.
Issues in study design
The large individual differences in SDLP values make it 
hard to directly compare individuals on their absolute SDLP 
values. Therefore, between-subject designs, for example 
comparing 2 groups, are an inefficient way to determine the 
effect of drugs on driving, as very large groups of subjects 
are needed for statistical significance. Matching subjects on 
SDLP before randomization may reduce variability, but even 
in the healthy volunteer studies that included very similar 
subjects with regards to driving history, SDLP was shown 
to differ considerably between subjects.
For driving research using SDLP as outcome mea-
sure, a within-subject crossover design is more efficient 
and   sensitive. SDLP is stable over time. Cross over designs 
allow the comparison of differences between a drug and 
a placebo, within subjects. Using this design, very compa-
rable results were obtained in different studies using the same 
methodology and design. This was shown for example in 
driving studies testing the residual effects of zopiclone.33–35
Dosage and time of testing
To understand the effects of a drug it is necessary to include 
more than one dosage of the drug under investigation. 
Preferably, studies include both the clinical dose and twice 
that dose. Any drug, regardless of half-life, can produce 
impairment of SDLP if the dose is high enough, or fail to 
produce impairment if the dose is low enough. Therefore, 
study designs including multiple dosing are preferred. 
For some drugs, dosages are determined on an individual 
basis. An example of individualized dosing can be found 
in patients with attention deficit hyperactivity disorder 
(ADHD). In such instances patients are preferably tested 
after receiving their individual tailored dosage,36 which 
then can be compared to a placebo and verum treatment. 
For other medications, dosages are titrated after an initial 
low starting dose. This happens for example with the use 
of selective serotonin reuptake inhibitors (SSRIs). Ideally, 
both the doses at the beginning of titration and the end of 
titration should be studied.
To test acute effects of drugs on driving, tests are generally 
scheduled at CMAX, ie, the time after administration when 
peak blood plasma concentration of the drug under investiga-
tion is reached. Sub-chronic effects can be tested after days 
or weeks, and patients should be retested especially after 
changing dosages.
If next-day or other delayed drug effects are expected 
one should not test driving ability solely at CMAX. For some 
drugs such as hypnotics it is essential to examine potential 
hangover effects on driving performance. Most study designs 
administer sleep medication at bedtime and test driving per-
formance the following morning, 9–10 hours after treatment 
administration. With long-acting hypnotics, additional tests 
in the afternoon, 16–17 hours after intake, are warranted.
Subject considerations
If one aims to demonstrate adverse effects on driving caused 
by a drug, the greatest sensitivity appears to be from a sample 
of healthy adult volunteers. To enhance generalizability both 
sexes should be studied. Participants should have sufficient 
driving experience to minimize learning effects during the 
study. Generally, a lower limit of 5 years of driving experi-
ence, and driving at least 5000 km per year is recommended 
to reach this goal. The results obtained with the healthy 
volunteer study can be the basis of further investigation 
of driving performance comparing specific groups such as 
elderly versus young/adult drivers, novice versus experienced 
drivers, or professional versus regular drivers. After healthy 
volunteer data is obtained, a second subject sample should 
reflect the target population that will use the drugs under 
investigation clinically. A disadvantage of including these 
patients is that there are many confounding variables that 
make interpretation of the study results difficult. For example, 
if depressed patients are included to test the effects of a new 
antidepressant on driving ability, improved driving may be 
seen as a result of therapeutic efficacy of the drug. At the 
same time, adverse effects of the medication may impair 
driving. These two effects then cancel each other out and 
make the study results hard to interpret. There are a number 
of potential subject/drug interactions which require collecting International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Table 2 Summary of generally observed differences and similarities between the on-the-road driving test, driving simulators, and 
psychometric tests
On-the-road driving test Driving simulators Psychometric tests
Familiarity with test high Medium Low
Learning effect Low Medium high
Simulator sickness N/A yes N/A
Risk of accidents yes No risk involved No risk involved
Motivation to perform test high Medium Medium/low
Unexpected events yes Controlled circumstances Controlled circumstances
Measures overall vehicle control yes yes Isolated skills tested
Duration of the test* Long Medium/long Short
Vigilance decrement* yes yes No
Notes: *In general psychometric tests used in driving research are of short duration and not designed to measure vigilance decrement. There are however psychometric 
tests, such as the Mackworth Clock test, specifically designed for this purpose.
Abbreviation: N/A, not applicable.
data in healthy volunteers to understand the direct drug effect. 
Therefore, testing only in patients is not   recommended. 
After obtaining data from healthy volunteers, data obtained 
from patients is easier to interpret.
Concluding remarks
The standardized on-the-road driving test has proven to be 
a sensitive and reliable method to examine driving ability 
after administration of CNS drugs. Its primary parameter, 
SDLP, is a stable measure of driving performance with high 
test–retest reliability. SDLP differences from placebo are 
dose-dependent, and do not depend on the subject’s baseline 
driving skills (placebo SDLP).
Strengths and weaknesses of the on-the-road driving test 
are summarized in Table 2.
Future innovations of on-road testing include measuring 
driving ability (including SDLP) in the driver’s own car over 
long periods of time. Pilot studies applying this naturalistic 
way of data collection are currently in progress.37
It is important that standard operation procedures are 
applied to conduct the test and analyze the data in order 
to allow comparisons between studies from different sites. 
Applying different data editing procedures, or shortening the 
test, has an impact on the study outcome (SDLP). We there-
fore advocate that researchers who use SDLP as a measure 
(either in a driving simulator or on-road) adopt the strategies 
discussed in this paper to conduct the test and edit the data.
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